The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly issued a notification to initiate direct payment settlement between the medical insurance fund and pharmaceutical suppliers for National Reimbursement Drug List (NRDL) negotiation drugs starting December 1, 2024. This move signifies a shift towards streamlining the reimbursement process for drugs included in the NRDL.
According to the notification, the medical insurance fund will directly settle payments for NRDL negotiation drugs procured by designated medical institutions through the provincial centralized procurement platform during the agreement period. However, for other NRDL negotiation drugs with expired agreements, price bidding drugs, and drugs sharing the same generic names as NRDL negotiation drugs, payments will continue to be settled by medical institutions and pharmaceutical suppliers in compliance with existing regulations.
The document emphasizes adherence to the principle of territorial management and hierarchical settlement. Medical insurance agencies at all levels will handle the direct settlement of NRDL negotiation drug payments for local medical institutions, entering into settlement agreements with both parties to define settlement methods and responsibilities. The provincial medical insurance fund management center will standardize the agreement templates between provincial medical insurance agencies and various medical institutions and suppliers. Timely execution of agreements, including bill push, agreement signing, settlement review, and payment disbursement, aims to ensure pharmaceutical companies receive timely and accurate payments.- Flcube.com
